In an international placebo-controlled phase 3 trial of 589 hospitalised adults, adding ensitrelvir to standard care did not significantly improve the day-60 recovery outcome. The result argues against broad inpatient benefit while leaving narrower timing or subgroup questions open.
Key findings
- In an international placebo-controlled phase 3 trial of 589 hospitalised adults, adding ensitrelvir to standard care did not significantly improve the day-60 recovery outcome. The result argues against broad inpatient benefit while leaving narrower timing or subgroup questions open.
Why this matters globally
This work adds internationally comparable evidence in Health sciences and defines questions for replication in other populations or systems. Its global value lies in the evidence and transferable reasoning, not in a single impact score.
Thai researcher contribution
Thailand-linked authors and Siriraj Hospital, Mahidol University, Khon Kaen University, Chulalongkorn University, HIV Netherlands Australia Thailand Research Collaboration contribute to the research network behind this work. Thai participation is identified from bibliographic affiliations and should be checked against the author list and source article.
Limitations to consider
Eligibility can limit generalisability; long-term and real-world outcomes remain important, and secondary or subgroup findings should not be overinterpreted.
Verify the original sources
Clinical Infectious DiseasesRead the original article↗DOI: 10.1093/cid/ciag272